Rein Therapeutics, Inc.
Rein Therapeutics, Inc. (RNTX): 3 pipeline candidates · ~4 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.2 months
D/E 1.27 · 8% dilution
Lead: Phase 2
3 candidates
N/A
5 buys · 0 sells (180d)
A transparent, data-derived signal for Rein Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$80.6M
Cash
$4.4M
Quarterly Burn
$3.4M
Runway
4.2 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
43
Total value held
$9.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,997,042 | $2.6M |
| bios capital management, lp | 1,982,375 | $2.6M |
| university of texas/texas am investment management co | 511,610 | $665K |
| prosight management, lp | 411,600 | $535K |
| geode capital management, llc | 344,690 | $448K |
| texas capital bank wealth management services inc | 273,625 | $356K |
| gagnon securities llc | 239,520 | $311K |
| senvest management, llc | 230,895 | $300K |
| palogic value management, l.p. | 180,000 | $234K |
| vanguard fiduciary trust co | 154,512 | $201K |
Showing top 10 of 43 institutional holders of Rein Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Rein Therapeutics, Inc.'s pipeline?
Rein Therapeutics, Inc. (RNTX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Rein Therapeutics, Inc.'s lead drug candidate?
Rein Therapeutics, Inc.'s most advanced tracked candidate is lti-01 (Phase 2) for Loculated pleural effusion (LPE).
What is Rein Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Rein Therapeutics, Inc. has approximately 4.2 months of cash runway.
What is Rein Therapeutics, Inc.'s market capitalization?
Rein Therapeutics, Inc.'s market capitalization is approximately $80.6M.
Who is the CEO of Rein Therapeutics, Inc.?
Dr. James Brian Windsor Ph.D. is the chief executive officer of Rein Therapeutics, Inc. (RNTX).
Get the full picture on Rein Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.